SAM
TVRD

Silvercrest Asset Management’s Tvardi Therapeutics TVRD Stock Holding History

Silvercrest Asset Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$192K Hold
101,034
– – ﹤0.01% 832
2026
Q1 		$321K Hold
101,034
– – ﹤0.01% 757
2025
Q4 		$434K Buy
101,034
+78,668
+352% +$705K ﹤0.01% 738
2025
Q3 		$872K Buy
+22,366
New +$637K 0.01% 627

Other funds holding TVRD

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Silvercrest Asset Management's TVRD Position: Q2 2026 in Review

Silvercrest Asset Management held its Tvardi Therapeutics (TVRD) position steady in Q2 2026 at 101,034 shares worth $192K. The position accounts for ﹤0.01% of the portfolio, ranked #832.

Silvercrest Asset Management first reported a position in TVRD in Q3 2025 and has held it in 4 quarters since. The position peaked at $872K in Q3 2025. 58 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • Silvercrest Asset Management held 101,034 shares of Tvardi Therapeutics worth $192K as of Q2 2026.
  • Silvercrest Asset Management left its Tvardi Therapeutics share count unchanged in Q2 2026.
  • Tvardi Therapeutics made up ﹤0.01% of Silvercrest Asset Management's portfolio in Q2 2026, its #832 holding.
  • Silvercrest Asset Management first reported a position in Tvardi Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Silvercrest Asset Management's Tvardi Therapeutics position peaked at $872K in Q3 2025.
  • 58 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Silvercrest Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.